This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsApontis Pharma（APPH）株式概要Apontis Pharma AGは、ドイツで内科系を適応症とする医療用医薬品のマーケティングと販売を行っている。 詳細APPH ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長4/6過去の実績2/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より93.1%で取引されている 収益は年間115.01%増加すると予測されています 今年は黒字化を達成 リスク分析高いレベルの非現金収入 すべてのリスクチェックを見るAPPH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€11.0043.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7m117m2016201920222025202620282031Revenue €117.4mEarnings €1.5mAdvancedSet Fair ValueView all narrativesApontis Pharma AG 競合他社PharmaSGP HoldingSymbol: HMSE:PSGMarket cap: €379.9mDermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.4bIldong HoldingsSymbol: KOSE:A000230Market cap: ₩95.5bNATURLAND Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo ReszvenytarsasagSymbol: BUSE:NATURLANDMarket cap: Ft39.0b価格と性能株価の高値、安値、推移の概要Apontis Pharma過去の株価現在の株価€11.0052週高値€12.2052週安値€9.34ベータ1.161ヶ月の変化4.76%3ヶ月変化4.27%1年変化12.24%3年間の変化18.79%5年間の変化n/aIPOからの変化-41.64%最新ニュースお知らせ • Jun 19Apontis Pharma AG, Annual General Meeting, Jul 29, 2025Apontis Pharma AG, Annual General Meeting, Jul 29, 2025, at 10:00 W. Europe Standard Time.お知らせ • Nov 21Shares of Apontis Pharma to Delist Following the Tender OfferZentiva said on November 19, 2024 that it has lifted the minimum acceptance threshold of 65% in its tender offer to acquire Germany's Apontis Pharma AG. Zentiva launched the offer in October, proposing EUR 10 per share. The planned deal values Apontis Pharma at EUR 85 million. Following the tender offer, Apontis Pharma shares will no longer be traded on the open market. A separate delisting bid will not be required, Zentiva said.Price Target Changed • Nov 15Price target decreased by 9.4% to €15.75Down from €17.38, the current price target is an average from 4 analysts. New target price is 66% above last closing price of €9.46. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year.お知らせ • Oct 24Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH).Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH) on October 24, 2024. A cash consideration valued at €10 per share will be paid by Zentiva AG. As part of consideration, an undisclosed value is paid towards common equity of Apontis Pharma AG. Through a German unit, Zentiva is offering €10 per share, which represents a premium of 52.9% over the closing price on October 15, or a day before the transaction was first announced. Apontis management and supervisory boards welcome the offer and plan to recommend shareholders to accept it. The Offer values APONTIS PHARMA at €85 million for 100% of share capital. Both the Management Board and the Supervisory Board of APONTIS PHARMA welcome the Offer. Subject to review of the Offer Document and in compliance with their fiduciary duties, both the Management Board and the Supervisory Board intend to support the Offer and to recommend all APONTIS PHARMA shareholders to accept the Offer. They have already confirmed that they will tender any APONTIS PHARMA shares held by them into the Offer. Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash consideration in the amount of EUR 9.00 per share, emphasizing the attractiveness of the offer price. Settlement of the Offer will be subject to customary offer conditions, including regulatory clearances. It also includes a minimum acceptance threshold of 65% of APONTIS PHARMA shares. The transaction is expected to close at the end of Q4 2024 or in Q1 2025.Reported Earnings • Aug 14First half 2024 earnings released: EPS: €0.084 (vs €0.42 loss in 1H 2023)First half 2024 results: EPS: €0.084 (up from €0.42 loss in 1H 2023). Revenue: €22.7m (up 19% from 1H 2023). Net income: €702.8k (up €4.22m from 1H 2023). Profit margin: 3.1% (up from net loss in 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€62.1m market cap, or US$67.8m).最新情報をもっと見るRecent updatesお知らせ • Jun 19Apontis Pharma AG, Annual General Meeting, Jul 29, 2025Apontis Pharma AG, Annual General Meeting, Jul 29, 2025, at 10:00 W. Europe Standard Time.お知らせ • Nov 21Shares of Apontis Pharma to Delist Following the Tender OfferZentiva said on November 19, 2024 that it has lifted the minimum acceptance threshold of 65% in its tender offer to acquire Germany's Apontis Pharma AG. Zentiva launched the offer in October, proposing EUR 10 per share. The planned deal values Apontis Pharma at EUR 85 million. Following the tender offer, Apontis Pharma shares will no longer be traded on the open market. A separate delisting bid will not be required, Zentiva said.Price Target Changed • Nov 15Price target decreased by 9.4% to €15.75Down from €17.38, the current price target is an average from 4 analysts. New target price is 66% above last closing price of €9.46. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year.お知らせ • Oct 24Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH).Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH) on October 24, 2024. A cash consideration valued at €10 per share will be paid by Zentiva AG. As part of consideration, an undisclosed value is paid towards common equity of Apontis Pharma AG. Through a German unit, Zentiva is offering €10 per share, which represents a premium of 52.9% over the closing price on October 15, or a day before the transaction was first announced. Apontis management and supervisory boards welcome the offer and plan to recommend shareholders to accept it. The Offer values APONTIS PHARMA at €85 million for 100% of share capital. Both the Management Board and the Supervisory Board of APONTIS PHARMA welcome the Offer. Subject to review of the Offer Document and in compliance with their fiduciary duties, both the Management Board and the Supervisory Board intend to support the Offer and to recommend all APONTIS PHARMA shareholders to accept the Offer. They have already confirmed that they will tender any APONTIS PHARMA shares held by them into the Offer. Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash consideration in the amount of EUR 9.00 per share, emphasizing the attractiveness of the offer price. Settlement of the Offer will be subject to customary offer conditions, including regulatory clearances. It also includes a minimum acceptance threshold of 65% of APONTIS PHARMA shares. The transaction is expected to close at the end of Q4 2024 or in Q1 2025.Reported Earnings • Aug 14First half 2024 earnings released: EPS: €0.084 (vs €0.42 loss in 1H 2023)First half 2024 results: EPS: €0.084 (up from €0.42 loss in 1H 2023). Revenue: €22.7m (up 19% from 1H 2023). Net income: €702.8k (up €4.22m from 1H 2023). Profit margin: 3.1% (up from net loss in 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€62.1m market cap, or US$67.8m).Price Target Changed • Apr 15Price target increased by 15% to €17.50Up from €15.17, the current price target is an average from 3 analysts. New target price is 104% above last closing price of €8.56. Stock is down 21% over the past year. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year.Price Target Changed • Apr 12Price target increased by 10% to €16.17Up from €14.67, the current price target is an average from 3 analysts. New target price is 112% above last closing price of €7.64. Stock is down 30% over the past year. The company is forecast to post earnings per share of €0.13 next year compared to a net loss per share of €1.36 last year.Reported Earnings • Mar 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €38.7m (down 31% from FY 2022). Net loss: €11.3m (down €14.0m from profit in FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Jan 20+ 3 more updatesApontis Pharma AG to Report Q1, 2024 Results on May 08, 2024Apontis Pharma AG announced that they will report Q1, 2024 results on May 08, 2024Price Target Changed • Nov 10Price target decreased by 15% to €16.13Down from €19.00, the current price target is an average from 3 analysts. New target price is 398% above last closing price of €3.24. Stock is down 56% over the past year. The company is forecast to post a net loss per share of €1.08 compared to earnings per share of €0.32 last year.お知らせ • Nov 09Apontis Pharma Provides Earnings Guidance for the Full Year 2023Apontis Pharma provides earnings guidance for the full year 2023. The company expects sales of EUR 36.1 million.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 31%After last week's 31% share price decline to €5.42, the stock trades at a trailing P/E ratio of 17.7x. Average forward P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 55% over the past year.お知らせ • Jul 29Apontis Pharma AG to Report First Half, 2023 Results on Aug 10, 2023Apontis Pharma AG announced that they will report first half, 2023 results on Aug 10, 2023お知らせ • Jul 12+ 1 more updateApontis Pharma AG Announces Board ChangesThe Chief Executive Officer (CEO), Karlheinz Gast of APONTIS PHARMA AG has informed the Supervisory Board that he is resigning from his office for personal reasons with immediate effect and that he is leaving the Executive Board. The Supervisory Board received and accepted Mr. Gast’s resignation at its extraordinary meeting on July 10, 2023. The service agreement with Mr. Gast will be canceled. At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date of 1 September 2023. Until then, Executive Board member Thomas Milz will head the company alone. Mr. Wohlschlegel (56) brings more than 26 years of experience in the pharmaceutical industry. He was Managing Director of Merck Serono GmbH until 2021 and responsible for the European business of Merck KGaA before that. Mr. Wohlschlegel is a recognized leader with an outstanding strategic and operational track record.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.68, the stock trades at a trailing P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 25% over the past year.お知らせ • Jun 29Aontis Pharma AG Launches Single Pill Finder and Distribution of Single Pill RosazimibAPONTIS PHARMA AG launched Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023. Single Pill Finder online application shows real-time options to simplify therapy. Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill. New Single Pill Rosazimib on the market. Further Single Pills to be marketed in 2023. Single Pills combine the established active ingredients in a single tablet in a daily single dose compared to loose combination therapy. The reduced number of tablets can increase adherence and thus contribute to improving prognosis, as demonstrated in the retrospective START and START 2.0 studies and the prospective SECURE study, among others. In addition, the new Single Pill Rosazimib is now available on the market, bringing the portfolio of already approved products in Germany to 11 Single Pills. As an online physician assistance system, the free-of-charge Single Pill Finder shows possible Single Pill options for simplifying therapy for patients on polymedication. Based on the existing nationally standardized medication plan for loose combination preparations, the physician receives real-time recommendations for substitution with Single Pills. The medication plan can be entered in manually, as a photo or uploaded as a scan via desktop, tablet, or smartphone. The results are presented in a smart sort order according to the degree to which the therapy can be simplified, e.g., the portion of single tablet substitutions. This makes it much easier for physicians to access solutions for simplifying therapies. The development for use under practice conditions was carried out with the participation of more than 400 physicians in Germany, according to the motto " by physicians for physicians". Launch of new Single Pill RosazIMib (AP - D01) continues APONTIS PHARMA's announced Single Pill portfolio expansion, providing substitution therapy for the loose combination of Rosuvastatin and Ezetimibe. Launched on 28 June 2023, indications include primaryhypercholesterolemia/homozygous familial hypercholesterolemia (HoFH) and prevention of cardiovascular events in patients with a history of coronary artery disease (CAD) and acute coronary syndrome.Price Target Changed • May 05Price target decreased by 9.4% to €25.67Down from €28.33, the current price target is an average from 3 analysts. New target price is 285% above last closing price of €6.66. Stock is down 55% over the past year. The company is forecast to post earnings per share of €0.07 for next year compared to €0.32 last year.Valuation Update With 7 Day Price Move • May 03Investor sentiment deteriorates as stock falls 36%After last week's 36% share price decline to €7.00, the stock trades at a forward P/E ratio of 100x. Average forward P/E is 20x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 52% over the past year.Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €58.4m (up 14% from FY 2021). Net income: €2.69m (up €3.43m from FY 2021). Profit margin: 4.6% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.86, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 24% over the past year.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.04, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 42% over the past year.Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 21% share price gain to €7.72, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 65% over the past year.Reported Earnings • Apr 02Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.088 loss per share (up from €0.18 loss in FY 2020). Revenue: €51.2m (up 30% from FY 2020). Net loss: €745.2k (loss narrowed 37% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 9.0%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany.株主還元APPHDE PharmaceuticalsDE 市場7D1.9%6.1%3.2%1Y12.2%27.3%2.5%株主還元を見る業界別リターン: APPH過去 1 年間で27.3 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: APPHは、過去 1 年間で2.5 % のリターンをもたらしたGermanマーケットと一致しました。価格変動Is APPH's price volatile compared to industry and market?APPH volatilityAPPH Average Weekly Movement2.0%Pharmaceuticals Industry Average Movement6.4%Market Average Movement6.1%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: APPH 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: APPHの 週次ボラティリティ ( 2% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1946137Sascha Glanemannapontis-pharma.deApontis Pharma AGは、ドイツで内科領域における医療用医薬品のマーケティングと販売を行っている。高血圧、高脂血症、二次予防などの循環器系疾患、呼吸器系疾患、糖尿病を中心に、単剤医薬品やその他の医薬品を提供している。同社は1946年に設立され、ドイツのモンハイム・アム・ラインに本拠を置く。2024年11月21日現在、Apontis Pharma AGはZentiva AGの子会社として運営されている。もっと見るApontis Pharma AG 基礎のまとめApontis Pharma の収益と売上を時価総額と比較するとどうか。APPH 基礎統計学時価総額€91.63m収益（TTM）€654.52k売上高(TTM)€51.77m140.0xPER（株価収益率1.8xP/SレシオAPPH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計APPH 損益計算書（TTM）収益€51.77m売上原価€21.66m売上総利益€30.11mその他の費用€29.46m収益€654.52k直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）0.079グロス・マージン58.16%純利益率1.26%有利子負債／自己資本比率0%APPH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/11/18 09:31終値2025/11/14 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Apontis Pharma AG 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Christian EhmannWarburg Research GmbH
NATURLAND Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo ReszvenytarsasagSymbol: BUSE:NATURLANDMarket cap: Ft39.0b
お知らせ • Jun 19Apontis Pharma AG, Annual General Meeting, Jul 29, 2025Apontis Pharma AG, Annual General Meeting, Jul 29, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Nov 21Shares of Apontis Pharma to Delist Following the Tender OfferZentiva said on November 19, 2024 that it has lifted the minimum acceptance threshold of 65% in its tender offer to acquire Germany's Apontis Pharma AG. Zentiva launched the offer in October, proposing EUR 10 per share. The planned deal values Apontis Pharma at EUR 85 million. Following the tender offer, Apontis Pharma shares will no longer be traded on the open market. A separate delisting bid will not be required, Zentiva said.
Price Target Changed • Nov 15Price target decreased by 9.4% to €15.75Down from €17.38, the current price target is an average from 4 analysts. New target price is 66% above last closing price of €9.46. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year.
お知らせ • Oct 24Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH).Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH) on October 24, 2024. A cash consideration valued at €10 per share will be paid by Zentiva AG. As part of consideration, an undisclosed value is paid towards common equity of Apontis Pharma AG. Through a German unit, Zentiva is offering €10 per share, which represents a premium of 52.9% over the closing price on October 15, or a day before the transaction was first announced. Apontis management and supervisory boards welcome the offer and plan to recommend shareholders to accept it. The Offer values APONTIS PHARMA at €85 million for 100% of share capital. Both the Management Board and the Supervisory Board of APONTIS PHARMA welcome the Offer. Subject to review of the Offer Document and in compliance with their fiduciary duties, both the Management Board and the Supervisory Board intend to support the Offer and to recommend all APONTIS PHARMA shareholders to accept the Offer. They have already confirmed that they will tender any APONTIS PHARMA shares held by them into the Offer. Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash consideration in the amount of EUR 9.00 per share, emphasizing the attractiveness of the offer price. Settlement of the Offer will be subject to customary offer conditions, including regulatory clearances. It also includes a minimum acceptance threshold of 65% of APONTIS PHARMA shares. The transaction is expected to close at the end of Q4 2024 or in Q1 2025.
Reported Earnings • Aug 14First half 2024 earnings released: EPS: €0.084 (vs €0.42 loss in 1H 2023)First half 2024 results: EPS: €0.084 (up from €0.42 loss in 1H 2023). Revenue: €22.7m (up 19% from 1H 2023). Net income: €702.8k (up €4.22m from 1H 2023). Profit margin: 3.1% (up from net loss in 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€62.1m market cap, or US$67.8m).
お知らせ • Jun 19Apontis Pharma AG, Annual General Meeting, Jul 29, 2025Apontis Pharma AG, Annual General Meeting, Jul 29, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Nov 21Shares of Apontis Pharma to Delist Following the Tender OfferZentiva said on November 19, 2024 that it has lifted the minimum acceptance threshold of 65% in its tender offer to acquire Germany's Apontis Pharma AG. Zentiva launched the offer in October, proposing EUR 10 per share. The planned deal values Apontis Pharma at EUR 85 million. Following the tender offer, Apontis Pharma shares will no longer be traded on the open market. A separate delisting bid will not be required, Zentiva said.
Price Target Changed • Nov 15Price target decreased by 9.4% to €15.75Down from €17.38, the current price target is an average from 4 analysts. New target price is 66% above last closing price of €9.46. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year.
お知らせ • Oct 24Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH).Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH) on October 24, 2024. A cash consideration valued at €10 per share will be paid by Zentiva AG. As part of consideration, an undisclosed value is paid towards common equity of Apontis Pharma AG. Through a German unit, Zentiva is offering €10 per share, which represents a premium of 52.9% over the closing price on October 15, or a day before the transaction was first announced. Apontis management and supervisory boards welcome the offer and plan to recommend shareholders to accept it. The Offer values APONTIS PHARMA at €85 million for 100% of share capital. Both the Management Board and the Supervisory Board of APONTIS PHARMA welcome the Offer. Subject to review of the Offer Document and in compliance with their fiduciary duties, both the Management Board and the Supervisory Board intend to support the Offer and to recommend all APONTIS PHARMA shareholders to accept the Offer. They have already confirmed that they will tender any APONTIS PHARMA shares held by them into the Offer. Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash consideration in the amount of EUR 9.00 per share, emphasizing the attractiveness of the offer price. Settlement of the Offer will be subject to customary offer conditions, including regulatory clearances. It also includes a minimum acceptance threshold of 65% of APONTIS PHARMA shares. The transaction is expected to close at the end of Q4 2024 or in Q1 2025.
Reported Earnings • Aug 14First half 2024 earnings released: EPS: €0.084 (vs €0.42 loss in 1H 2023)First half 2024 results: EPS: €0.084 (up from €0.42 loss in 1H 2023). Revenue: €22.7m (up 19% from 1H 2023). Net income: €702.8k (up €4.22m from 1H 2023). Profit margin: 3.1% (up from net loss in 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€62.1m market cap, or US$67.8m).
Price Target Changed • Apr 15Price target increased by 15% to €17.50Up from €15.17, the current price target is an average from 3 analysts. New target price is 104% above last closing price of €8.56. Stock is down 21% over the past year. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year.
Price Target Changed • Apr 12Price target increased by 10% to €16.17Up from €14.67, the current price target is an average from 3 analysts. New target price is 112% above last closing price of €7.64. Stock is down 30% over the past year. The company is forecast to post earnings per share of €0.13 next year compared to a net loss per share of €1.36 last year.
Reported Earnings • Mar 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €38.7m (down 31% from FY 2022). Net loss: €11.3m (down €14.0m from profit in FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Jan 20+ 3 more updatesApontis Pharma AG to Report Q1, 2024 Results on May 08, 2024Apontis Pharma AG announced that they will report Q1, 2024 results on May 08, 2024
Price Target Changed • Nov 10Price target decreased by 15% to €16.13Down from €19.00, the current price target is an average from 3 analysts. New target price is 398% above last closing price of €3.24. Stock is down 56% over the past year. The company is forecast to post a net loss per share of €1.08 compared to earnings per share of €0.32 last year.
お知らせ • Nov 09Apontis Pharma Provides Earnings Guidance for the Full Year 2023Apontis Pharma provides earnings guidance for the full year 2023. The company expects sales of EUR 36.1 million.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 31%After last week's 31% share price decline to €5.42, the stock trades at a trailing P/E ratio of 17.7x. Average forward P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 55% over the past year.
お知らせ • Jul 29Apontis Pharma AG to Report First Half, 2023 Results on Aug 10, 2023Apontis Pharma AG announced that they will report first half, 2023 results on Aug 10, 2023
お知らせ • Jul 12+ 1 more updateApontis Pharma AG Announces Board ChangesThe Chief Executive Officer (CEO), Karlheinz Gast of APONTIS PHARMA AG has informed the Supervisory Board that he is resigning from his office for personal reasons with immediate effect and that he is leaving the Executive Board. The Supervisory Board received and accepted Mr. Gast’s resignation at its extraordinary meeting on July 10, 2023. The service agreement with Mr. Gast will be canceled. At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date of 1 September 2023. Until then, Executive Board member Thomas Milz will head the company alone. Mr. Wohlschlegel (56) brings more than 26 years of experience in the pharmaceutical industry. He was Managing Director of Merck Serono GmbH until 2021 and responsible for the European business of Merck KGaA before that. Mr. Wohlschlegel is a recognized leader with an outstanding strategic and operational track record.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.68, the stock trades at a trailing P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 25% over the past year.
お知らせ • Jun 29Aontis Pharma AG Launches Single Pill Finder and Distribution of Single Pill RosazimibAPONTIS PHARMA AG launched Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023. Single Pill Finder online application shows real-time options to simplify therapy. Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill. New Single Pill Rosazimib on the market. Further Single Pills to be marketed in 2023. Single Pills combine the established active ingredients in a single tablet in a daily single dose compared to loose combination therapy. The reduced number of tablets can increase adherence and thus contribute to improving prognosis, as demonstrated in the retrospective START and START 2.0 studies and the prospective SECURE study, among others. In addition, the new Single Pill Rosazimib is now available on the market, bringing the portfolio of already approved products in Germany to 11 Single Pills. As an online physician assistance system, the free-of-charge Single Pill Finder shows possible Single Pill options for simplifying therapy for patients on polymedication. Based on the existing nationally standardized medication plan for loose combination preparations, the physician receives real-time recommendations for substitution with Single Pills. The medication plan can be entered in manually, as a photo or uploaded as a scan via desktop, tablet, or smartphone. The results are presented in a smart sort order according to the degree to which the therapy can be simplified, e.g., the portion of single tablet substitutions. This makes it much easier for physicians to access solutions for simplifying therapies. The development for use under practice conditions was carried out with the participation of more than 400 physicians in Germany, according to the motto " by physicians for physicians". Launch of new Single Pill RosazIMib (AP - D01) continues APONTIS PHARMA's announced Single Pill portfolio expansion, providing substitution therapy for the loose combination of Rosuvastatin and Ezetimibe. Launched on 28 June 2023, indications include primaryhypercholesterolemia/homozygous familial hypercholesterolemia (HoFH) and prevention of cardiovascular events in patients with a history of coronary artery disease (CAD) and acute coronary syndrome.
Price Target Changed • May 05Price target decreased by 9.4% to €25.67Down from €28.33, the current price target is an average from 3 analysts. New target price is 285% above last closing price of €6.66. Stock is down 55% over the past year. The company is forecast to post earnings per share of €0.07 for next year compared to €0.32 last year.
Valuation Update With 7 Day Price Move • May 03Investor sentiment deteriorates as stock falls 36%After last week's 36% share price decline to €7.00, the stock trades at a forward P/E ratio of 100x. Average forward P/E is 20x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 52% over the past year.
Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €58.4m (up 14% from FY 2021). Net income: €2.69m (up €3.43m from FY 2021). Profit margin: 4.6% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.86, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 24% over the past year.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.04, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 42% over the past year.
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 21% share price gain to €7.72, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 65% over the past year.
Reported Earnings • Apr 02Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.088 loss per share (up from €0.18 loss in FY 2020). Revenue: €51.2m (up 30% from FY 2020). Net loss: €745.2k (loss narrowed 37% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 9.0%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany.
